Download Files:
Deucravacitinib
$190 – $2,250
Products Details
Product Description
– Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA’s world first de novo deuterium, is available for study in moderate to severe plaque psoriasis[1][2].
Web ID
– HY-117287
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H19D3N8O3
References
– [1]Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18.|[2]Catlett I, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Annals of the Rheumatic Diseases 2017;76:859.
CAS Number
– 1609392-27-9
Molecular Weight
– 425.46
Compound Purity
– 99.87
SMILES
– O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]
Clinical Information
– Launched
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 33.33 mg/mL (ultrasonic)
Target
– IFNAR;Interleukin Related;JAK
Isoform
– IL-12;IL-23;JAK1;Tyk2
Pathway
– Epigenetics;Immunology/Inflammation;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
